We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers (FPA008-003)

This study is currently recruiting participants.
Verified March 2017 by Five Prime Therapeutics, Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02526017
First Posted: August 18, 2015
Last Update Posted: March 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Five Prime Therapeutics, Inc.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2019
  Estimated Primary Completion Date: May 2019 (Final data collection date for primary outcome measure)